Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Avidity Biosciences, Inc. (RNA) Total Non-Current Liabilities (2019 - 2020)

Avidity Biosciences' Total Non-Current Liabilities history spans 2 years, with the latest figure at $26.0 million for Q3 2020.

  • For Q3 2020, Total Non-Current Liabilities changed N/A year-over-year to $26.0 million; the TTM value through Sep 2020 reached $26.0 million, changed N/A, while the annual FY2019 figure was $27.5 million, N/A changed from the prior year.
  • Total Non-Current Liabilities reached $26.0 million in Q3 2020 per RNA's latest filing, up from $25.1 million in the prior quarter.
  • In the past five years, Total Non-Current Liabilities ranged from a high of $27.5 million in Q4 2019 to a low of $25.1 million in Q2 2020.